Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

Launched by SANOFI · Feb 18, 2013

Keywords

ClinConnect Summary

The study duration by subject will include a 8-week treatment period with 3 follow-up visits.

Gender

ALL

Eligibility criteria

• Inclusion criteria :
• • Satisfying International Classification of Disease-10 (ICD) diagnostic criteria of schizophrenia;
• • Positive and Negative Syndrome Scale (PANSS) total score ≥ 60
• Exclusion criteria:
• • Refractory schizophrenia or Patients treated with sufficient clozapine for a minimum period of 6-8 weeks without improvement;
• • Participation into another clinical trial within the last month;
• • Patients previously or currently treated with amisulpride;
• • Patients receiving clozapine within the past 1 month or treated with long-acting formulation of antipsychotic medication within the past 2 months;
• • Patients receiving electric convulsive therapy or physical therapy within the past 1 month;
• • Patients with coexisting severe systemic diseases;
• • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.